MENLO PARK, CA – October 2, 2013 – AtheroMed, a developer of innovative technologies for treating peripheral artery disease (PAD), announced that it has completed patient enrollment in the EASE clinical study. The EASE study results will be presented by Dr. Stephen Williams, Director, Vascular Medicine Center at Johns Hopkins University, during a Late Breaking Clinical Trials Session on Wednesday, October 9th, at the Vascular Interventional Advances (VIVA) conference in Las Vegas.
The EASE study was a prospective, multi-center, single-arm study to evaluate the safety and effectiveness of the Phoenix Atherectomy System for the treatment of de-novo and restenotic lesions of lower extremity arteries. The study was conducted under an IDE to support US FDA clearance and enrolled 105 patients at 16 sites in the US and Germany. Outcome assessments were made after the baseline procedure and at 30-day and 6-month follow-up visits. Co-Principal Investigators of the study were Dr. Thomas Davis, St. John Hospital (Detroit, MI), and Dr. James McKinsey, Columbia Presbyterian Hospital (New York, NY).
“Peripheral arterial disease, especially blockages located below the knee, continues to present challenges, even with currently available technologies,” said Dr. Davis. “Based on my case results in the EASE study, the Phoenix Atherectomy System appears promising as a front-line therapy for treating PAD.”
Read more: http://www.atheromedinc.com/atheromed-announces-completion-of-patient-enrollment-in-the-ease-study-evaluating-the-phoenix-atherectomy-system-in-treating-pad/
AtheroMed announces completion of patient enrollment in the EASE study evaluating the Phoenix Atherectomy System in treating PAD
MALVERN, Pa., August 19, 2013 – TetraLogic Pharmaceuticals, a biopharmaceutical company
Santa Clara, CA, July 24, 2013 — ProteinSimple today introduced the FluorChem R system as the next member of the FluorChem product family. The FluorChem R system is a fully integrated, multimode gel and Western blot imager with chemiluminescent, fluorescent, and infrared detection capabilities.
ViaCyte, Inc. raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes
San Diego, California, July 10, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that it completed a private equity financing transaction, providing the Company $10.6 million through the sale of Series C-1 Preferred Stock, together with warrants to purchase stock. The financing, conducted as a rights offering to ViaCyte Series B and C Preferred Stock holders, included the Company’s largest existing investors – Johnson & Johnson Development Corporation, Sanderling Ventures and Asset Management Company (Johnson Trust).
Judy Twist shares with Lisa her success with the program Prevent.
Two big names in lifestyle change development for diabetes prevention are joining forces to bring their technologies to more participants. Omada Health offers its Prevent program that combines a curriculum, coaching, and social support to motivate people with pre-diabetes to change dangerous aspects of their lifestyles. Viridian Health Management, meanwhile, has been rolling out its My Weigh 2 Prevent Diabetes program in more than 30 states. Both are based on the curriculum of the National Diabetes Prevention Program (National DPP) which was developed as part of an NIH study supported by the CDC that showed that modest lifestyle modifications can lead to significant reduction in the chance of developing diabetes. While Viridian’s program relies on face-to-face coaching at clinics and community centers, Omada’s is an online program, so the partnership will help channel people toward the programs more appropriate for them.
GUEST MENTOR Sean Duffy, CEO and co-founder of Omada Health: No entrepreneur can — or should — go it alone. But beyond hiring some teammates in the trenches, you’ll also need a handful of people working with you from the sidelines. Your advisers and board of directors are there to provide the high-level input that is difficult to get when you’re in the weeds.
Tornier Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Over-Allotment Option
AMSTERDAM--(BUSINESS WIRE)-- Tornier, N.V. (NASDAQ: TRNX), a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, announced today the closing of the previously announced underwritten public offering of 8.05 million ordinary shares at a public offering price of $16.15 per ordinary share. The shares sold include 1.05 million ordinary shares sold pursuant to the option to purchase additional shares granted by Tornier and certain existing shareholders to the underwriters, which was exercised in full. Tornier received net proceeds from this offering of approximately $78.8 million, after deducting underwriters' discounts and commissions and estimated expenses.
Cryoablation: lnterventional radiologists present results of research on a new minimally invasive treatment option for advanced cancers that have spread to lung tissue.
Frozen balls of ice can safely kill cancerous tumors that have spread to the lungs, according to the first prospective multicenter trial of cryoablation. The results are being presented at the Society oflnterventional Radiology’s 38th Annual Scientific Meeting in New Orleans.
Omada Health Secures $4.7M From USVP, NEA, Kapor & More To Roll Out Its Online Diabetes Prevention Program
Back in December 2011, Omada Health grabbed $800K in seed funding from a long list of notable investors, including NEA, Aberdare, Kapor Capital, TriplePoint Ventures and Esther Dyson. After a year of testing, the funding enabled the startup to launch Prevent, its flagship product and the “first-ever online diabetes prevention program for the general public,” Omada Health founder Sean Duffy said at the time.